Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
2.
Eur J Intern Med ; 97: 69-77, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34844795

RESUMEN

AIMS: To evaluate pulmonary and intravascular congestion at admission and repeatedly during hospitalization for acute decompensated heart failure (ADHF) in HFrEF and HFpEF patients using lung (LUS) and inferior vena cava (IVC) ultrasound. METHODS AND RESULTS: Three-hundred-fourteen patients (82±9 years; HFpEF =172; HFrEF=142) admitted to Internal Medicine wards for ADHF were enrolled in a multi-center prospective study. At admission HFrEF presented higher indexes of pulmonary and intravascular congestion (LUS-score: 0.9 ±â€¯0.4 vs 0.7 ±â€¯0.4; p<0.01; IVC end-expiratory diameter: 21.6 ±â€¯5.1 mm vs 20±5.5 mm, p<0.01; IVC collapsibility index 24.4 ±â€¯17.4% vs 30.9 ±â€¯21.1% p<0.01) and higher Nt-proBNP values (8010 vs 3900 ng/l; p<0.001). At discharge, HFrEF still presented higher B-scores (0.4 ±â€¯4 vs 0.3 ±â€¯0.4; p = 0.023), while intravascular congestion improved to a greater extent, thus IVC measurements were similar in the two groups. No differences in diuretic doses, urine output, hemoconcentration, worsening renal function were found. At 90-days follow up HF readmission/death did not differ in HFpEF and HFrEF (28% vs 31%, p = 0,48). Residual congestion was associated with HF readmission/death considering the whole population; while intravascular congestion predicted readmission/death in the HFrEF, no association between sonographic indexes and the outcome was found in HFpEF. CONCLUSIONS: Serial assessment of pulmonary and intravascular congestion revealed a higher burden of fluid overload in HFrEF and, conversely, a greater reduction in intravascular venous congestion with diuretic treatment. Although other factors beyond EF could play a role in congestion/decongestion patterns, our data may be relevant for further phenotyping HF patients, considering the importance of decongestion optimization in the clinical approach.


Asunto(s)
Insuficiencia Cardíaca , Diuréticos/uso terapéutico , Insuficiencia Cardíaca/complicaciones , Insuficiencia Cardíaca/tratamiento farmacológico , Insuficiencia Cardíaca/epidemiología , Hospitalización , Humanos , Pronóstico , Estudios Prospectivos , Volumen Sistólico
3.
Parasit Vectors ; 8: 566, 2015 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-26515286

RESUMEN

Unfortunately, the original version of this article [1] contained an error. Figure 1 in the original article, corresponded to the first coinertia analysis that was carried out with no data on the procyclin PE repeats for the T. brucei brucei strains. After including these data, the coinertia analysis was modified both in the directionality of the arrows in the Y Hyperspace and in the biplot generated by the interaction of the two coinertia axes. The modified coinertia analysis is included in Fig. 1.

4.
Parasit Vectors ; 8: 536, 2015 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-26467019

RESUMEN

BACKGROUND: Livestock trypanosomoses, caused by three species of the Trypanozoon subgenus, Trypanosoma brucei brucei, T. evansi and T. equiperdum is widely distributed throughout the world and constitutes an important limitation for the production of animal protein. T. evansi and T. equiperdum are morphologically indistinguishable parasites that evolved from a common ancestor but acquired important biological differences, including host range, mode of transmission, distribution, clinical symptoms and pathogenicity. At a molecular level, T. evansi is characterized by the complete loss of the maxicircles of the kinetoplastic DNA, while T. equiperdum has retained maxicircle fragments similar to those present in T. brucei. T. evansi causes the disease known as Surra, Derrengadera or "mal de cadeiras", while T. equiperdum is the etiological agent of dourine or "mal du coit", characterized by venereal transmission and white patches in the genitalia. METHODS: Nine Venezuelan Trypanosoma spp. isolates, from horse, donkey or capybara were genotyped and classified using microsatellite analyses and maxicircle genes. The variables from the microsatellite data and the Procyclin PE repeats matrices were combined using the Hill-Smith method and compared to a group of T. evansi, T. equiperdum and T. brucei reference strains from South America, Asia and Africa using Coinertia analysis. Four maxicircle genes (cytb, cox1, a6 and nd8) were amplified by PCRfrom TeAp-N/D1 and TeGu-N/D1, the two Venezuelan isolates that grouped with the T. equiperdum STIB841/OVI strain. These maxicircle sequences were analyzed by nucleotide BLAST and aligned toorthologous genes from the Trypanozoon subgenus by MUSCLE tools. Phylogenetic trees were constructed using Maximum Parsimony (MP) and Maximum Likelihood (ML) with the MEGA5.1® software. RESULTS: We characterized microsatellite markers and Procyclin PE repeats of nine Venezuelan Trypanosoma spp. isolates with various degrees of virulence in a mouse model, and compared them to a panel of T. evansi and T. equiperdum reference strains. Coinertia analysis of the combined repeats and previously reported T. brucei brucei microsatellite genotypes revealed three distinct groups. Seven of the Venezuelan isolates grouped with globally distributed T. evansi strains, while TeAp-N/D1 and TeGu-N/D1 strains clustered in a separate group with the T. equiperdum STIB841/OVI strain isolated in South Africa. A third group included T. brucei brucei, two strains previously classified as T. evansi (GX and TC) and one as T. equiperdum (BoTat-1.1). Four maxicircle genes, Cytochrome b, Cythocrome Oxidase subunit 1, ATP synthase subunit 6 and NADH dehydrogenase subunit 8, were identified in the two Venezuelan strains clustering with the T. equiperdum STIB841/OVI strain. Phylogenetic analysis of the cox1 gene sequences further separated these two Venezuelan T. equiperdum strains: TeAp-N/D1 grouped with T. equiperdum strain STIB818 and T. brucei brucei, and TeGu-N/D1 with the T. equiperdum STIB841/OVI strain. CONCLUSION: Based on the Coinertia analysis and maxicircle gene sequence phylogeny, TeAp-N/D1 and TeGu-N/D1 constitute the first confirmed T. equiperdum strains described from Latin America.


Asunto(s)
ADN de Cinetoplasto , Genes Protozoarios , Variación Genética , Genotipo , Repeticiones de Microsatélite , Trypanosoma/clasificación , Trypanosoma/genética , Animales , Análisis por Conglomerados , ADN Protozoario/química , ADN Protozoario/genética , Equidae/parasitología , Caballos/parasitología , Datos de Secuencia Molecular , Filogenia , Roedores/parasitología , Análisis de Secuencia de ADN , Homología de Secuencia , Trypanosoma/aislamiento & purificación , Venezuela
5.
Bone Marrow Transplant ; 45(7): 1147-53, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19898504

RESUMEN

BEAM is a widely used conditioning regimen for relapsed/refractory lymphoma patients undergoing auto-SCT. We conducted a multicenter study with an alternative regimen (fotemustine plus etoposide, cytarabine and melphalan (FEAM)) in which BCNU was substituted by the chloroethylnitrosourea fotemustine (FTM). Eighty-four patients with relapsed/refractory Hodgkin's (n=20) and non-Hodgkin's lymphoma (n=64) were conditioned with a FEAM regimen (FTM 150 mg/m(2) on days -7, -6, etoposide 200 mg/m(2) and cytarabine 400 mg/m(2) on days -5, -4, -3, -2 and melphalan 140 mg/m(2) on day -1). Patients were evaluated for toxicity and engraftment parameters. Median times to neutrophil (>500 x 10(9)/l) and plt (>20 000 x 10(9)/l) engraftment were 11 and 13 days, respectively. Grade 3 mucositis occurred in 19 patients (23%), while G3 nausea/vomiting and G3 diarrhea were observed in 13 (15%) and 6 (7%) patients, respectively. No severe hepatic, renal or pulmonary toxicity was detected. Seven patients (7%) experienced G4 mucositis, while no other G4 toxicities or unexpected adverse events of any grade were recorded. Transplant-related mortality was 2.4%. We conclude that a FEAM regimen is feasible and safe. Although toxicity and engraftment times compared favorably with BEAM, longer follow-up is needed to evaluate fully its efficacy and long-term safety.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Linfoma/terapia , Acondicionamiento Pretrasplante/métodos , Adolescente , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Citarabina/administración & dosificación , Etopósido/administración & dosificación , Estudios de Factibilidad , Supervivencia de Injerto , Trasplante de Células Madre Hematopoyéticas/mortalidad , Humanos , Cinética , Masculino , Melfalán/administración & dosificación , Persona de Mediana Edad , Compuestos de Nitrosourea/administración & dosificación , Compuestos Organofosforados/administración & dosificación , Tasa de Supervivencia , Acondicionamiento Pretrasplante/efectos adversos , Trasplante Autólogo , Resultado del Tratamiento , Adulto Joven
6.
Bone Marrow Transplant ; 45(1): 123-7, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19483762

RESUMEN

The aim of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving high-dose (HD)-CT with auto-SCT, and the efficacy of a second dose of palonosetron in treating breakthrough emesis. One hundred thirty-four patients treated with HD-CT and auto-SCT for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of conditioning; patients were also administered dexamethasone throughout the entire period of conditioning. If breakthrough emesis occurred, a second dose of palonosetron was administered at 72 h after the first administration. Complete response and complete protection were observed in 36 and 26% of patients, respectively. One-half of the patients, re-treated with palonosetron for breakthrough emesis, were successfully rescued. Treatment with palonosetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV and treatment of breakthrough emesis in the setting of HD-CT.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Dexametasona/administración & dosificación , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Isoquinolinas/administración & dosificación , Quinuclidinas/administración & dosificación , Acondicionamiento Pretrasplante/efectos adversos , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Náusea/prevención & control , Palonosetrón , Antagonistas de la Serotonina/administración & dosificación , Trasplante Autólogo/efectos adversos , Vómitos/inducido químicamente , Vómitos/prevención & control
7.
Vet Parasitol ; 161(3-4): 194-200, 2009 May 12.
Artículo en Inglés | MEDLINE | ID: mdl-19286320

RESUMEN

Nine Trypanosoma sp. Venezuelan isolates, initially presumed to be T. evansi, were collected from three different hosts, capybara (Apure state), horse (Apure state) and donkey (Guarico state) and compared by the random amplification polymorphic DNA technique (RAPD). Thirty-one to 46 reproducible fragments were obtained with 12 of the 40 primers that were used. Most of the primers detected molecular profiles with few polymorphisms between the seven horse, capybara and donkey isolates. Quantitative analyses of the RAPD profiles of these isolates revealed a high degree of genetic conservation with similarity coefficients between 85.7% and 98.5%. Ten of the primers generated polymorphic RAPD profiles with two of the three Trypanosoma sp. horse isolates, namely TeAp-N/D1 and TeGu-N/D1. The similarity coefficient between these two isolates and the rest, ranged from 57.9% to 68.4% and the corresponding dendrogram clustered TeAp-N/D1 and Te Gu-N/D1 in a genetically distinct group.


Asunto(s)
ADN Protozoario/genética , Técnica del ADN Polimorfo Amplificado Aleatorio , Trypanosoma/genética , Trypanosoma/aislamiento & purificación , Animales , Secuencia de Bases , ADN Protozoario/clasificación , Variación Genética , Filogenia , Trypanosoma/clasificación , Venezuela
8.
Support Care Cancer ; 17(12): 1469-73, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19294429

RESUMEN

INTRODUCTION: The aim of our study was to evaluate the efficacy of a single-dose palonosetron plus dexamethasone to control emesis in patients (pts) receiving HEC. Moreover, we evaluated the amount of their food intake (FI) in the week following therapy, in order to measure any reduction of calories consumption related to Chemotherapy-induced nausea and vomiting (CINV). METHODS: Patients affected with advanced cancer were treated with palonosetron 250 mcg plus dexamethasone 20 mg before HEC. Nausea, vomiting, and FI were monitored by a 7-day diary. Complete Response (CR: no vomiting and no rescue therapy) was the primary endpoint, Complete Control (CC: CR and no more than mild nausea) and the evaluation of FI were the secondary endpoints. The endpoints were evaluated during the acute (0-24 h), the delayed (25-168 h) and overall (0-168 h) phases. RESULTS: Thirty-five patients were enrolled; 85.7% and 82.9% of patients achieved CR and CC respectively, during the acute phase; 82.9% and 77.1% of patients achieved CR and CC, during the delayed phase; 80% and 77.1% of patients achieved CR and CC, during the overall phase. During the acute phase, patients with a CC without nausea had a median daily FI of 1,575 kcal, whereas patients with CC and presence of mild nausea had a median daily FI of 1,040 kcal (-535 kcal; p < 0.0001). CONCLUSIONS: Our preliminary results confirm the efficacy of a single-dose palonosetron plus dexamethasone to prevent both acute and delayed nausea and vomiting. Moreover, the efficacy of palonosetron in nausea and vomiting control seems to warrant adequate caloric intake in these patients.


Asunto(s)
Antieméticos/uso terapéutico , Dexametasona/uso terapéutico , Isoquinolinas/uso terapéutico , Quinuclidinas/uso terapéutico , Antagonistas de la Serotonina/uso terapéutico , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Quimioterapia Combinada , Ingestión de Alimentos/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Náusea/prevención & control , Neoplasias/tratamiento farmacológico , Palonosetrón , Estudios Prospectivos , Vómitos/inducido químicamente , Vómitos/prevención & control
9.
Exp Parasitol ; 121(1): 1-7, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18848544

RESUMEN

Trypanosoma evansi is the causative agent of equine trypanosomosis, disease that affects horse's productivity and health. Parasitological and molecular methods are mostly used to detect the infection. The aim of this work was evaluate PCR sensitivity to detect T. evansi using the primers 21/22-mer, ITS1, ESAG 6/7 and TBR 1/2 designed from repetitive (multicopies) genomic sequences. The results were compare with two parasitological tests in mice, micro-haematocrite centrifugation technique and direct microscopic examination. The results shows (a) that the minimum amount of DNA from blood of highly parasitaemic mice that was detectable by PCR was 0.001 ng, using the ESAG6/7 and TBR1/2 primer, (b) using TBR1/2 primer for parasites purified could detect 0.000001 ng and (c) in the prepatent period PCR detect the presence of parasites earlier than parasitological techniques. Nevertheless, the percentage of detection for PCR varies depending on primer employed with 60% and 66% for ITS1 and 21/22-mer, and 80% for ESAG6/7 and TBR1/2. Consequently, TBR1/2 and ESAG6/7 were the best primers to monitor T. evansi infections in mice. For epidemiological application, such comparative evaluation should be made for detection of T. evansi in livestock such as horses.


Asunto(s)
Reacción en Cadena de la Polimerasa/veterinaria , Trypanosoma/aislamiento & purificación , Tripanosomiasis/veterinaria , Animales , Bovinos , Centrifugación , Cartilla de ADN/química , ADN Protozoario/análisis , ADN Protozoario/sangre , Modelos Animales de Enfermedad , Equidae , Femenino , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/parasitología , Caballos , Ratones , Parasitemia/diagnóstico , Parasitemia/parasitología , Parasitemia/veterinaria , Reacción en Cadena de la Polimerasa/normas , Roedores , Sensibilidad y Especificidad , Trypanosoma/genética , Tripanosomiasis/diagnóstico , Tripanosomiasis/parasitología
10.
Bone Marrow Transplant ; 41(11): 977-81, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18425147

RESUMEN

This study aimed to identify which graft product subset of CD34+ cells might be the most predictive of early hematopoietic recovery following allogeneic peripheral SCT (allo-PBSCT). The relationship between the number of 'mature' subsets of CD34+ cells (CD34+/CD33+, CD34+/CD38+, CD34+/DR+ and CD34+/CD133-) and 'immature' subsets of CD34+ cells (CD34+/CD33-, CD34+/CD38-, CD34+/DR- and CD34+/CD133+) and early neutrophil and platelet engraftment were studied in a homogeneous series (for disease, pre transplant chemotherapy, conditioning regimen and GVHD prophylaxis) of 30 AML patients after allo-PBSCT from HLA-identical siblings. In our experience, the total CD34+/CD133+ cell number was inversely correlated with the days required for the recovery of 0.5 x 10(9)/l neutrophils (r=or-0.82, P=0.02) and platelets of 20 x 10(9)/l (r=or-0.60, P=0.06); this correlation was better than the total CD34+ cell dose and neutrophil (r=or-0.70, P=0.04) and platelet engraftment (r=or-0.56, P=0.07). We suggest that a high number of CD34+/CD133+ PBSC may be associated with faster neutrophil and platelet recovery; these findings may help to predict the repopulating capacity of PBSC in patients after allo-PBSCT, especially when a relatively low number of CD34+ cells is infused.


Asunto(s)
Antígenos CD34 , Supervivencia de Injerto/inmunología , Leucemia Mieloide Aguda/terapia , Trasplante de Células Madre de Sangre Periférica/métodos , Antígeno AC133 , Adolescente , Adulto , Antígenos CD , Diferenciación Celular , Estudios de Cohortes , Femenino , Glicoproteínas , Enfermedad Injerto contra Huésped/prevención & control , Prueba de Histocompatibilidad , Humanos , Masculino , Persona de Mediana Edad , Péptidos , Relaciones entre Hermanos , Células Madre/clasificación , Células Madre/citología , Trasplante Homólogo
11.
Bone Marrow Transplant ; 37(8): 719-24, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16518434

RESUMEN

Haemopoietic stem cell therapy is an increasingly adopted procedure in the treatment of patients with malignant lymphoma. In this retrospective analysis, we evaluated 262 patients, 57 (22%) with Hodgkin's and 205 (78%) with non-Hodgkin's lymphomas (NHL), and 665 harvesting procedures in order to assess the impact of poor mobilization on survival and to determine the factors that may be predictive of CD34(+) poor mobilization. The mobilization chemotherapy regimens consisted of high-dose cyclophosphamide in 92 patients (35.1%) and a high-dose cytarabine-containing regimen (DHAP in 87 patients -(33.2%), MAD in 83 (31.7%)). The incidence of poor mobilizers (<2 x 10(6) CD34(+) cells/kg) was 17.9% overall, with a 10% of very poor mobilizers (< or = 1 x 10(6)/kg). Refractory disease status and chemotherapeutic load (>3 regimens) before mobilization played a negative role and were associated with poor mobilization. Survival analysis of all harvested patients showed an overall survival at 3 years of 71% in good mobilizers vs 33% in poor mobilizers (P=0.002). The event-free survival at 3 years was 23% in poor mobilizers and 58% in good mobilizers (P=0.04). We conclude that in NHL patients, poor mobilization status is predictive of survival.


Asunto(s)
Movilización de Célula Madre Hematopoyética/métodos , Linfoma/terapia , Trasplante de Células Madre de Sangre Periférica/métodos , Adulto , Antígenos CD34/biosíntesis , Antineoplásicos/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Citometría de Flujo , Trasplante de Células Madre Hematopoyéticas , Humanos , Linfoma/metabolismo , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Análisis Multivariante , Pronóstico , Estudios Retrospectivos , Células Madre/metabolismo , Factores de Tiempo , Resultado del Tratamiento
12.
Exp Parasitol ; 111(2): 126-9, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16023641

RESUMEN

Trypanosoma vivax is the principal etiological agent of bovine trypanosomosis, a widely disseminated disease in tropical and subtropical regions. Here, we present a simple and reproducible method for the purification of T. vivax from experimentally infected and immunosuppressed sheep, using an isopycnic Percoll gradient, followed by DEAE-cellulose chromatography, with an estimated yield of 11-15%. This method could be used for the purification of T. vivax geographical isolates from various locations and from different natural hosts.


Asunto(s)
Parasitemia/veterinaria , Enfermedades de las Ovejas/parasitología , Trypanosoma vivax/aislamiento & purificación , Tripanosomiasis Africana/veterinaria , Animales , Centrifugación Isopicnica/veterinaria , Cromatografía DEAE-Celulosa/veterinaria , Terapia de Inmunosupresión , Parasitemia/inmunología , Parasitemia/parasitología , Proteínas Protozoarias/análisis , Ovinos , Enfermedades de las Ovejas/inmunología , Trypanosoma vivax/química , Tripanosomiasis Africana/inmunología , Tripanosomiasis Africana/parasitología
13.
Bone Marrow Transplant ; 29(4): 285-90, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11896424

RESUMEN

Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients. The study included 72 patients with NHL (42 follicular and 30 large cells). The mean age was 37 years (range 17-60). Sixty-four patients (88.9%) had stage III-IV disease. Forty-eight patients (66.7%) had bone marrow involvement. Systemic B symptoms were present in 42 patients (58.3%). Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34 (47.2%) and the results of 132 procedures were analyzed. At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy). Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product. The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34+ cell yield, for optimal engraftment. Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica , Cisplatino , Ciclofosfamida/administración & dosificación , Citarabina , Dexametasona , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Movilización de Célula Madre Hematopoyética/métodos , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/terapia , Adolescente , Adulto , Femenino , Movilización de Célula Madre Hematopoyética/efectos adversos , Trasplante de Células Madre Hematopoyéticas , Humanos , Recuento de Leucocitos , Linfoma no Hodgkin/sangre , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Trasplante Autólogo
15.
J Parasitol ; 86(5): 1137-40, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11128495

RESUMEN

Schistosoma mansoni egg antigens are mostly responsible for the granulomatous pathology in human intestinal schistosomiasis. Several previous studies have indicated that the induction of an immune response against some parasite enzymes may protect against pathology. The present work was designed to identify enzyme activities present in a standard soluble egg antigen (SEA) preparation. Simple colorimetric analyses were performed incubating SEA with 2-naphthyl, 2-naphthylamide (2NA), or p-nitrophenyl substrates at different pHs in the absence of added effectors. Results showed prominent acid phosphatase (pH 5.4), alkaline phosphatase (pH 8.5), and N-acetyl-beta-glucosaminidase (pH 5.4) activities. Relevant peptidase activities were also detected at pH 6.5-7.5 against 2NA derivatives of (1) aliphatic (alpha-Ala > beta-Ala > Leu > Met > S-benzyl-Cys), polar (Ser > Gln), basic (Arg > Lys > ornithine), and acidic (Glu) amino acids; (2) dipeptides: X-Ala (X = Gly > Leu > Lys > Asp), X-Arg (X = Ala > Arg > Phe > Gly > Pro > Asp), Ser-Met, and Phe-Pro; and (3) tripeptides (Ala-Phe-Pro > Phe-Pro-Ala). The data demonstrated that S. mansoni SEA contains a rich set of hydrolases with different specificities that might play a role in the egg physiology and possibly also in the host-parasite relationships.


Asunto(s)
Antígenos Helmínticos/metabolismo , Hidrolasas/metabolismo , Schistosoma mansoni/enzimología , Animales , Cricetinae , Óvulo/inmunología , Schistosoma mansoni/crecimiento & desarrollo , Schistosoma mansoni/inmunología , Esquistosomiasis mansoni/parasitología
16.
Eur J Gynaecol Oncol ; 20(4): 258-61, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10475117

RESUMEN

The poor prognosis of malignant rhabdoid tumor is emphasized and histopathological criteria for distinction from epithelial sarcoma of the vulva are discussed. Immunohistochemical analyses were performed by using nine different antigens including vimentin, cytokeratin, epithelial membrane antigen, carcinoembryonic antigen, desmin, muscle-specific actin, S-100 protein, AP-15, neuron specific enolase. This is the sixth reported case of a malignant rhabdoid tumor of the vulva. The patient died eight months after the initial diagnosis in spite of a combination of surgery, adjuvant chemotherapy and external radiotherapy.


Asunto(s)
Tumor Rabdoide/patología , Neoplasias de la Vulva/patología , Adulto , Biomarcadores de Tumor/metabolismo , Resultado Fatal , Femenino , Humanos , Inmunohistoquímica , Queratinas/metabolismo , Neoplasias Pulmonares/secundario , Metástasis Linfática/patología , Recurrencia Local de Neoplasia/diagnóstico , Tumor Rabdoide/metabolismo , Neoplasias Cutáneas/secundario , Vimentina/metabolismo , Neoplasias de la Vulva/metabolismo
17.
J Neurobiol ; 35(3): 258-70, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9622009

RESUMEN

Neurotrophins play an essential role in sensory development by providing trophic support to neurons that innervate peripheral targets. Nerve growth factor (NGF), neurotrophin-3, neurotrophin-4, and brain-derived neurotrophin exert their survival effect by binding to two transmembrane receptor types: trk receptors, which exhibit binding specificity, and the p75NTR receptor, which binds all neurotrophins. To determine how target-derived neurotrophins affect sensory neuron development and function, we used transgenic mice that overexpress NGF in the skin to examine the impact of NGF overexpression on receptor expression. Previous studies of trk expression in trigeminal ganglia of adult NGF transgenics showed that the percentage of trkA neurons doubled and their number increased fivefold. The present study focused on the p75 receptor and shows that the percentage of neurons expressing p75NTR also increase in NGF ganglia, but only by 10%. This increase did not encompass the small, BS-IB-4 isolectin-positive cells as they remained p75 negative in transgenic ganglia. Interestingly, levels of trkA protein were not increased on a per-cell level, whereas levels of p75NTR increased nearly threefold. These results show that in sensory systems, target-derived NGF modulates the level of p75NTR receptor expression, and in so doing, may act to regulate the formation of functional receptor complexes and subsequent trophic action.


Asunto(s)
Ganglios Sensoriales/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Lectinas de Plantas , Receptores de Factor de Crecimiento Nervioso/metabolismo , Animales , Lectinas/metabolismo , Ratones , Ratones Transgénicos/genética , Factores de Crecimiento Nervioso/genética , Neuronas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptor de Factor de Crecimiento Nervioso , Receptor trkA , Piel/metabolismo , Ganglio del Trigémino/citología , Ganglio del Trigémino/metabolismo
18.
J Cell Biol ; 134(2): 487-97, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8707832

RESUMEN

Target-derived influences of nerve growth factor on neuronal survival and differentiation are well documented, though effects of other neurotrophins are less clear. To examine the influence of NT-3 neurotrophin overexpression in a target tissue of sensory and sympathetic neurons, transgenic mice were isolated that overexpress NT-3 in the epidermis. Overexpression of NT-3 led to a 42% increase in the number of dorsal root ganglia sensory neurons, a 70% increase in the number of trigeminal sensory neurons, and a 32% increase in sympathetic neurons. Elevated NT-3 also caused enlargement of touch dome mechanoreceptor units, sensory end organs innervated by slowly adapting type 1 (SA1) neurons. The enlarged touch dome units of the transgenics had an increased number of associated Merkel cells, cells at which SA1s terminate. An additional alteration of skin innervation in NT-3 transgenics was an increased density of myelinated circular endings associated with the piloneural complex. The enhancement of innervation to the skin was accompanied by a doubling in the number of sensory neurons expressing trkC. In addition, measures of nerve fibers in cross-sectional profiles of cutaneous saphenous nerves of transgenics showed a 60% increase in myelinated fibers. These results indicate that in vivo overexpression of NT-3 by the epidermis enhances the number of sensory and sympathetic neurons and the development of selected sensory endings of the skin.


Asunto(s)
Ganglios Simpáticos/citología , Folículo Piloso/inervación , Mecanorreceptores/fisiología , Factores de Crecimiento Nervioso/fisiología , Neuronas Aferentes/citología , Animales , Axones/fisiología , Secuencia de Bases , Recuento de Células , ADN Complementario , Ganglios Simpáticos/ultraestructura , Expresión Génica , Células de Merkel/citología , Ratones , Ratones Transgénicos , Datos de Secuencia Molecular , Factores de Crecimiento Nervioso/biosíntesis , Factores de Crecimiento Nervioso/genética , Neuronas Aferentes/ultraestructura , Neurotrofina 3 , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptor trkC , Receptores de Factor de Crecimiento Nervioso/metabolismo , Piel/inervación
19.
J Cell Biol ; 128(1-2): 157-69, 1995 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7529766

RESUMEN

To examine the role of keratin intermediate filament proteins in cell structure and function, transgenic mice were isolated that express a modified form of the human K14 keratin protein in liver hepatocytes. A modified K14 cDNA (K14.P) sequence was linked downstream of the mouse transthyretin (TTR) gene promoter and enhancer elements to achieve targeted expression in hepatocytes. Hepatocytes expressing high levels of the transgene were found to have abnormal keratin filament networks as detected by indirect immunofluorescence using an antibody specific for the transgene product. Light and electron microscopic level histological analysis of isolated liver tissue showed in many cases degenerative changes that included inflammatory infiltration, ballooning degeneration, an increase in fat containing vacuoles, and glycogen accumulation. These changes were most evident in older mice over four months of age. No indication of typical Mallory body structures were identified at either the light or electron microscopic level. To evaluate secretory function in transgenic livers, bile acid secretion rates were measured in isolated perfused liver and found to be approximately twofold lower than aged-matched controls. These findings indicate that expression of an abnormal keratin in liver epithelial cells in the in vivo setting can alter the structure and function of a tissue and suggest a role of the keratin network in cellular secretion.


Asunto(s)
Epidermis/metabolismo , Queratinas/biosíntesis , Hígado/anomalías , Hígado/metabolismo , Animales , Bilis/metabolismo , Carcinoma Hepatocelular , Clonación Molecular , Humanos , Inmunohistoquímica , Hígado/patología , Neoplasias Hepáticas , Ratones , Ratones Transgénicos , Microscopía Electrónica , Prealbúmina/biosíntesis , Prealbúmina/genética , Valores de Referencia , Transfección , Células Tumorales Cultivadas
20.
Int J Gynecol Pathol ; 14(1): 39-44, 1995 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7883424

RESUMEN

To ascertain whether uterine malignant mixed müllerian tumors are biologically distinct from high-grade endometrial carcinomas (FIGO grade 3), we compared patient survival in 32 and 39 cases, respectively. The Cox proportional hazard model was employed to determine whether tumor type was an independent predictor of survival. The survival of patients with MMMT was also compared to that of patients with serous adenocarcinoma and clear cell carcinoma. The 5-year overall and disease-free survival were significantly lower for malignant mixed müllerian tumors (25% and 11%) than for high-grade endometrial carcinomas (64% and 56%). Using the Cox proportional hazard model, tumor type (MMMT vs. high-grade endometrial carcinoma) was a statistically significant predictor of survival after other important prognostic variables such as pathologic stage, depth of myometrial invasion, and vascular invasion had been taken into account. The increased aggressiveness of MMMT appears most attributable to their tendency to reach a more advanced stage by the time of clinical presentation and to their greater propensity for upper abdominal dissemination. The survival of patients with MMMT was also lower than that of patients with the special histologic variants of endometrial carcinoma, serous adenocarcinoma and clear cell carcinoma, which are recognized for their unusually aggressive clinical behavior. These results indicate that uterine malignant mixed müllerian tumors are clinically more aggressive than high-grade endometrial carcinomas and should continue to be recognized as a distinct entity.


Asunto(s)
Adenocarcinoma de Células Claras/patología , Cistadenocarcinoma Seroso/patología , Neoplasias Endometriales/patología , Tumor Mulleriano Mixto/patología , Adenocarcinoma de Células Claras/mortalidad , Adenocarcinoma de Células Claras/terapia , Terapia Combinada , Cistadenocarcinoma Seroso/mortalidad , Cistadenocarcinoma Seroso/terapia , Neoplasias Endometriales/mortalidad , Neoplasias Endometriales/terapia , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Tumor Mulleriano Mixto/mortalidad , Tumor Mulleriano Mixto/terapia , Estadificación de Neoplasias , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA